Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RobecoSAM was a Swiss-based investment specialist focused exclusively on Sustainability Investing, offering asset management, impact analysis, and sustainability assessments. Founded in 1995 as Sustainable Asset Management (SAM), the firm was a pioneer in ESG (Environmental, Social, and Governance) research and was the co-founder of the Dow Jones Sustainability Indices (DJSI). The company managed various thematic funds, including those focused on water, energy, and healthy living, which invested in global healthcare and life sciences companies. In 2019, S&P Global acquired RobecoSAM's ESG ratings business, and in 2020, its remaining investment management functions were fully integrated into its parent company, Robeco.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RobecoSAM.